卢比卡丁诱导的血小板减少症：体表面积的作用。
Lurbinectedin-induced thrombocytopenia: the role of body surface area.
机构信息
Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, 5841 S. Maryland Ave., MC 2115, Chicago, IL, 60637, USA.
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.
出版信息
Cancer Chemother Pharmacol. 2022 May;89(5):573-575. doi: 10.1007/s00280-022-04422-6. Epub 2022 Apr 1.
Abstract
Lurbinectedin is an alkylating agent approved for the second-line treatment of small cell lung cancer. Although initial studies showed no association between body surface area (BSA) and drug clearance, the recommended dose is 3.2 mg/m every 3 weeks. This recommendation was based on an exposure-response study, which demonstrated that patients with lower BSA had a higher incidence of thrombocytopenia. Herein we present the factors associated with BSA and thrombopoiesis, which may have contributed to the observed relationship.
摘要
鲁比卡丁是一种烷化剂，被批准用于小细胞肺癌的二线治疗。尽管最初的研究表明，体表面积（BSA）与药物清除率之间没有关联，但推荐剂量为每 3 周 3.2 毫克/平方米。这一推荐是基于一项暴露-反应研究得出的，该研究表明 BSA 较低的患者血小板减少症的发生率更高。在此，我们介绍了与 BSA 和血小板生成相关的因素，这些因素可能导致了观察到的关系。
相似文献
1
Lurbinectedin-induced thrombocytopenia: the role of body surface area.
Cancer Chemother Pharmacol. 2022 May;89(5):573-575. doi: 10.1007/s00280-022-04422-6. Epub 2022 Apr 1.
2
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
J Clin Pharmacol. 2021 Sep;61(9):1206-1219. doi: 10.1002/jcph.1886. Epub 2021 Jun 9.
3
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Cancer Chemother Pharmacol. 2022 May;89(5):585-594. doi: 10.1007/s00280-021-04366-3. Epub 2021 Nov 5.
4
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.
Sci Rep. 2024 Feb 13;14(1):3598. doi: 10.1038/s41598-024-54223-5.
5
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
Clin Cancer Res. 2014 Apr 15;20(8):2205-14. doi: 10.1158/1078-0432.CCR-13-1880. Epub 2014 Feb 21.
6
A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Invest New Drugs. 2022 Feb;40(1):91-98. doi: 10.1007/s10637-021-01142-1. Epub 2021 Aug 28.
7
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27.
8
Lurbinectedin for the treatment of small cell lung cancer.
Drugs Today (Barc). 2021 Jun;57(6):377-385. doi: 10.1358/dot.2021.57.6.3294559.
9
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
J Clin Oncol. 2018 Nov 1;36(31):3134-3143. doi: 10.1200/JCO.2018.78.6558. Epub 2018 Sep 21.
10
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11.
本文引用的文献
1
Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Cancer Chemother Pharmacol. 2022 May;89(5):585-594. doi: 10.1007/s00280-021-04366-3. Epub 2021 Nov 5.
2
Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
J Clin Pharmacol. 2021 Sep;61(9):1206-1219. doi: 10.1002/jcph.1886. Epub 2021 Jun 9.
3
Estrogens as regulator of hematopoietic stem cell, immune cells and bone biology.
Life Sci. 2021 Mar 15;269:119091. doi: 10.1016/j.lfs.2021.119091. Epub 2021 Jan 18.
4
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
Clin Cancer Res. 2021 May 1;27(9):2378-2382. doi: 10.1158/1078-0432.CCR-20-3901. Epub 2020 Dec 7.
5
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
J Natl Cancer Inst. 2021 Apr 6;113(4):400-407. doi: 10.1093/jnci/djaa124.
6
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27.
7
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity.
Oncoimmunology. 2019 Sep 5;8(11):e1656502. doi: 10.1080/2162402X.2019.1656502. eCollection 2019.
8
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Clin Colorectal Cancer. 2019 Jun;18(2):110-115.e2. doi: 10.1016/j.clcc.2018.12.006. Epub 2018 Dec 28.
9
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
Clin Pharmacokinet. 2019 Mar;58(3):363-374. doi: 10.1007/s40262-018-0701-2.
10
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Br J Cancer. 2017 Aug 22;117(5):628-638. doi: 10.1038/bjc.2017.205. Epub 2017 Jul 6.
Zotero 插件